GlassScriptPhysician profile
Alexander S Kaye
NPI 1720010986
$1,719.71
in general payments reported to CMS, 2019-2025
30 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.97 · 2020: $128 · 2021: $252 · 2022: $237 · 2023: $375 · 2024: $279 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $298.42 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $220.64 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $204.79 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.55 | 2025 | Caplyta |
| Pfizer INC. | $104.63 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.57 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $79.56 | 2020-2021 | |
| Inspire Medical Systems, INC. | $63.88 | 2023-2024 | Inspire |
| Eisai INC. | $54.09 | 2020-2021 | |
| Gilead Sciences, INC. | $48.38 | 2024 | |
| Astellas Pharma US INC | $40.97 | 2019-2023 | Myrbetriq |
| Xeris Pharmaceuticals, INC. | $40.22 | 2023-2024 | Keveyis |
| Supernus Pharmaceuticals, INC. | $36.60 | 2019-2020 | |
| Axsome Therapeutics, INC. | $31.67 | 2025 | Symbravo |
| Lilly USA, LLC | $27.22 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.73 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $26.24 | 2022 | |
| Acella Pharmaceuticals, LLC | $20.75 | 2024 | NP Thyroid 60 |
| Harmony Biosciences LLC | $19.92 | 2023 | Wakix |
| Dexcom, INC. | $18.76 | 2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $17.31 | 2023 | |
| Novo Nordisk INC | $16.93 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.90 | 2025 | Jornay Pm |
| Zyla Life Sciences, INC. | $16.45 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.50 | 2022 | |
| Boston Scientific Corporation | $14.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.79 | 2023 | Eliquis |
| Ibsa Pharma INC. | $14.47 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.74 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Kaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.